ESRRA and colonic neoplasm: First, to determine whether or not XCT790 might be a specific antagonist of ERRα expression in colon cancer cell lines [57, 58], we used CCD-18co normal colon fibroblasts and a panel of nine different colon cancer cell lines, including colon cancer cells expressing wild-type p53 (HCT-116p53+/+ and Lim1215), p53 mutant (missense or GOF; HT-29, DLD-1, HCT-15, SW480, and WiDr), and p53-deficient (HCT-116p53−/− and Caco-2) cells.